A Phase 1, Open Label Study to evaluate the safety Pharmacokinetic, Pharmacodynamic and clinical activity of PF-06863135, A B-Cell Maturation Antigen (BCMA)- CD3 Bispecifi Antibody In Patient
Clinical Trial Grant
Awarded By
Pfizer, Inc.
Start Date
March 7, 2018
End Date
April 30, 2023
Awarded By
Pfizer, Inc.
Start Date
March 7, 2018
End Date
April 30, 2023